What to Expect from the Report
The 2022 ESMO Annual Meeting is over, but the connections, data, and information shared at the conference will stay with us. Our team of analysts have carefully screened all the ESMO 2022 abstracts and identified 24 (18 clinical, 5 preclinical) abstracts relating to adoptive cell drugs and trials, and added them to the Beacon Adoptive Cell database.
This report encompasses a detailed analysis of the 24 abstracts in the adoptive cell space, including; clinical abstracts by phase, trial outline summaries and preclinical and clinical abstract summaries.
You will also find a full summary of all 24 adoptive cell abstracts ordered by; therapeutic class, target distribution and disease distribution. The abstract summaries include the following data; the name and link to the drug (on Beacon), trial sponsor/developer, abstract/ trial ID, phase, disease indication and description/dosing.
Find out more
The data from this post-conference report is available on the Beacon Adoptive Cell platform.
Speak with our Expert Team
Our dedicated team is on hand to showcase how Beacon can help you find the answers to your Adoptive Cell questions.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements.
